| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
AtriCure, Inc.$34.28
-0.28 (-0.81%)
C 44Pipeline Score MedTech · Commercial
Market Cap
1.31 B
EPS
-0.10
P/E Ratio
-268.26 $
Value Trade
15.42 M
SEC Financials
Q1 2026Dilution Risk
Revenue
141.25 M
R&D Expenses
24.23 M
Operating CF
-4.00 M
Total Assets
643.99 M
Total Liabilities
152.29 M
Equity
491.69 M
D/E Ratio
12,345
-0.21 %
Week
2.17 %
1 Month
-12.63 %
3 Month
-15.07 %
6 Month
-60.8 %
5 Year
133.8 %
All Time
Cash Data
Cash Position
146.16 M
Monthly Burn
1.33 M
Runway
107.8 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
563.63 K
52 Week Range
25.36 - 43.18
% held by Insiders
4.13 %
% held by Institutions
100.46 %
Enterprise Value
1.24 B
Total Shares
50.61 M
Short %
9.15 %
Float Shares
48.64 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AtriCure, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Drug Pipeline Intelligence
C44
Pipeline Score $998M
Pipeline ValueValuation Signal
3
Drugs Scored0.8x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 911)
Percentile RankAtriCure, Inc. carries a moderate pipeline score (44/100), with $2.5B risk-adjusted pipeline value, led by AtriCure Bipolar System in Atrial Fibrillation (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AtriCure Bipolar System Unknown | Atrial Fibrillation | Phase 3 | NCT00560885 | 46% | $2.0B | COMPLETED | 55 | - | - | Dec 1, 2012 | - | Mar 29, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
hybrid Convergent procedure | atrial fibrillation | — | 2020-05-08 | effectiveness difference: 18%; MAE rate: 7.8%; performance goal: 12%; Afib burden reduction: >90%; advantage over control: >23% Read More | May 8 , 20 20  AtriCure Announces Results from CONVERGE IDE Clinical Trial  R esults presented virtually via Heart Rhythm 365 Platform ; show s primary effectiveness superiority in f Read More | |
hybrid Convergent procedure | atrial fibrillation | — | 2020-05-08 | effectiveness difference: 18%; MAE rate: 7.8%; performance goal: 12%; Afib burden reduction: >90%; advantage over control: >23% Read More | May 8 , 20 20  AtriCure Announces Results from CONVERGE IDE Clinical Trial  R esults presented virtually via Heart Rhythm 365 Platform ; show s primary effectiveness superiority in f Read More | |
hybrid Convergent procedure | atrial fibrillation | — | 2020-05-08 | effectiveness difference: 18%; MAE rate: 7.8%; performance goal: 12%; Afib burden reduction: >90%; advantage over control: >23% Read More | May 8 , 20 20  AtriCure Announces Results from CONVERGE IDE Clinical Trial  R esults presented virtually via Heart Rhythm 365 Platform ; show s primary effectiveness superiority in f Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATRC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATRC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATRC▲ +6.9%on this news
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure is set to announce its financial results for the second quarter of 2026. The announcement is expected to provide insights into the company's performance during this period. Further details regarding the specific date and time of the announcement have not been disclosed.
Read more →ATRCAtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure is set to participate in the Goldman Sachs 47th Annual Global Health Care Conference. The event is a significant platform for discussing advancements in health care. Further details on AtriCure's agenda or focus during the conference have not been provided.
Read more →ATRCAtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. reported its financial results for the first quarter of 2026, revealing a worldwide revenue of $141.2 million, which marks a 14.3% increase compared to the same period last year. The company achieved net income of $0.1 million and an adjusted EBITDA of $17.1 million, showcasing improved profitability. U.S. revenue accelerated by 14.9%, supported by strong sales of key products including AtriClip and cryoSPHERE MAX. AtriCure expects continued growth with projected 2026 revenue between $600 million to $610 million.
Read more →ATRCAtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
AtriCure, Inc. will participate in the 2026 Bank of America Securities Health Care Conference. The management is set to engage in a fireside chat on May 12, 2026. This event will be accessible via a live audio webcast on the company's investor relations website. AtriCure is noted for its innovative technologies in treating atrial fibrillation and related conditions.
Read more →ATRCAtriCure to Announce First Quarter 2026 Financial Results
AtriCure is set to announce its financial results for the first quarter of 2026. This announcement is anticipated by stakeholders and may provide insights into the company's performance. The specific details of the results have not been disclosed yet.
Read more →ATRCAtriCure to Participate in the Citizens Life Sciences Conference
AtriCure, Inc. will participate in the Citizens Life Sciences Conference on March 10, 2026. The company's management will engage in a fireside chat, accessible via a live audio webcast. AtriCure is recognized for its innovative technologies in treating atrial fibrillation and related conditions, with a significant global impact.
Read more →ATRCAtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
AtriCure, Inc. announced its financial results for Q4 2025 and the full year of 2025, highlighting a 13.1% increase in quarterly revenue to $140.5 million. The company achieved a net income of $1.8 million in Q4, alongside a positive adjusted EBITDA of $19.9 million. Although the full year saw a net loss of $11.4 million, there was notable revenue growth of 14.9% year-over-year, driven by new product adoption. Looking forward, AtriCure projects 2026 revenue to reach approximately $600-$610 million, indicating continued growth ambitions.
Read more →ATRCAtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
AtriCure, Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026. An audio webcast will be held at 4:30 p.m. ET to discuss these results. AtriCure is known for its innovative technologies in treating atrial fibrillation and related conditions, with a significant global impact.
Read more →ATRC▼ -9.2%on this news
Provides Financial Outlook for 2026
AtriCure, Inc. has announced preliminary financial results for the fourth quarter and full year of 2025, indicating a strong expected growth trajectory. For 2026, the company projects revenues between $600 million and $610 million, supported by positive cash flow and an increase in product adoption. The company has also reported a positive adjusted EBITDA outlook for the upcoming year, reflecting robust financial performance. These figures follow a successful year marked by innovation in surgical treatments for atrial fibrillation and related conditions.
Read more →ATRCAtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
AtriCure, Inc. will participate in the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company's management will present at 10:30 a.m. PST, and interested parties can access the live audio webcast via their website. AtriCure is known for its innovative technologies in treating atrial fibrillation and related conditions.
Read more →ATRCAtriCure Announces the First Patients Treated with Novel Dual Energy Platform
AtriCure, Inc. has announced the successful first-in-human treatments using its new dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures, performed in Australia, demonstrated significant reductions in ablation time, enhancing surgical efficiency. However, the technologies are not yet approved for market use, and clinical trials are expected to commence next year.
Read more →ATRCAtriCure Reports Third Quarter 2025 Financial Results Raises Financial Outlook for 2025
AtriCure, Inc. reported third quarter financial results for 2025, showing significant year-over-year revenue growth of 15.8% to $134.3 million. The net loss decreased to $0.3 million, marking an improvement of $7.6 million from the previous year. Adjusted EBITDA rose by $9.9 million to $17.8 million, demonstrating strong operational performance. The company raised its full year revenue guidance to approximately $532 million to $534 million and continues to focus on expanding its suite of surgical products for atrial fibrillation management.
Read more →ATRCAtriCure Reports Second Quarter 2025 Financial Results Raises Financial Outlook for 2025
AtriCure, Inc. reported a robust second quarter for 2025 with revenues reaching $136.1 million, up 17.1% year over year. Despite a net loss of $6.2 million, the company showed improved adjusted EBITDA of $15.4 million. The completion of 6,500 patient enrollments in the LeAAPS trial marks a significant advancement for AtriCure. The company raised its financial outlook for 2025, expecting revenues between $527 million and $533 million, demonstrating confidence in its growth trajectory.
Read more →ATRCAtriCure Reports First Quarter 2025 Financial Results
AtriCure reported its first quarter 2025 financial results, showing a revenue increase to $123.6 million, up 13.6% year over year. The company also improved its net loss to $6.7 million, an enhancement of $6.5 million compared to the previous year. Adjusted EBITDA rose to $8.8 million, marking a significant $6.0 million increase year over year. Management forecasts a projected revenue range of $517 million to $527 million for the full year 2025, highlighting optimism in continued growth.
Read more →ATRCAtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which
AtriCure, Inc. has outlined its commitment to innovation and clinical science as it navigates through forward-looking statements regarding future growth opportunities. The company is strategically expanding its market presence in various cardiac and pain management sectors while emphasizing the importance of robust education and awareness initiatives. Recent changes in CMS guidelines and the introduction of new surgical codes may further support its operational efforts, enhancing patient access to cutting-edge treatments. Overall, AtriCure appears poised for sustained growth in upcoming years amidst evolving healthcare landscapes.
Read more →ATRCAtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
AtriCure, Inc. reported impressive financial results for the fourth quarter and full year 2024, showcasing a net revenue increase of 16.6% and 16.5% respectively. The growth was attributed to successful product launches and deeper market penetration. However, the company also noted an increase in operational losses and a significant net loss per share. Looking ahead, AtriCure projects a revenue target for 2025 of approximately $517 million to $527 million, indicating continued growth potential despite some financial challenges.
Read more →ATRC▲ +9.5%on this news· ran to +20% by day 3
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024,
AtriCure, Inc. reported strong preliminary financial results for the fourth quarter and full year of 2024, with projected revenues of $124.3 million for Q4 and $465.3 million for the year. The company highlighted a growth of 17% and expressed optimism for continued momentum in 2025, while factoring in some challenges within their U.S. Hybrid franchise. Management also provided financial guidance for 2025 with expected revenues between $517 million to $527 million and plans for an Analyst Investor Day to discuss their portfolio and future initiatives.
Read more →ATRCAtriCure Reports Third Quarter 2024 Financial Results
AtriCure, Inc. reported a strong performance for the third quarter of 2024, with worldwide revenue of $115.9 million, reflecting a year-over-year increase of 17.9%. Key drivers include robust sales in the U.S. market, notably in open appendage management devices, and significant international growth. Despite a slight sequential decline in revenue due to seasonal procedures, the company generated positive cash flow and improved its adjusted EBITDA. However, a loss from operations remains a concern, even though it showed improvement from the previous year.
Read more →ATRCAtriCure Reports Second Quarter 2024 Financial Results
AtriCure, Inc. reported its financial results for the second quarter of 2024, highlighting a 15.2% increase in worldwide revenue to $116.3 million. The company generated positive cash flow of $8.1 million and saw significant growth in both U.S. and international markets. However, despite overall revenue growth, the operating loss and decreased gross margin raised some concerns. Looking ahead, AtriCure projects full-year 2024 revenue growth of approximately 15% amidst ongoing clinical initiatives and new product introductions.
Read more →ATRCAtriCure Reports First Quarter 2024 Financial Results
AtriCure, Inc. reported its first quarter financial results for 2024, showcasing a 16.4% increase in worldwide revenue to $108.9 million. U.S. revenue grew by 15.4%, driven by strong sales in key product lines, although there was some pressure in minimally invasive appendage management products. The company forecasts full-year 2024 revenue growth of 15% to 17% over 2023, with an expected adjusted EBITDA increase. Despite these positive trends, AtriCure experienced an increase in operational losses compared to the previous year.
Read more →ATRC▲ +5.1%on this news
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
AtriCure, Inc. reported strong financial results for the fourth quarter and full year 2023, with worldwide revenue increasing 21.0% year-over-year to $106.5 million. The company's total revenue for 2023 was $399.2 million, marking a 20.8% increase. While AtriCure improved its financial metrics, including adjusted EBITDA, it also showed a net loss for the year. Looking ahead, the company projects continued revenue growth in 2024, estimated between $459 million to $466 million.
Read more →ATRC▲ +6.1%on this news
Provides Financial Outlook for 2024
AtriCure, Inc. announced its preliminary financial results for the fourth quarter and full year of 2023, revealing a projected Q4 revenue of $106.5 million, reflecting a 21% increase from the previous year. The company forecasts 2024 revenue to be between $459 million and $466 million, marking a growth of 15% to 17%. Strong performance in its innovative therapies contributed to this positive outlook, as management anticipates significant growth and operational leverage in the upcoming year.
Read more →ATRCAtriCure Appoints Shlomi Nachman to the Board of Directors
AtriCure, Inc. has appointed Shlomi Nachman to its Board of Directors, signaling a strategic move towards leveraging his extensive experience in the medical device industry. Nachman previously held senior roles at Johnson & Johnson and brings over 25 years of knowledge, particularly in the atrial fibrillation market. He expressed enthusiasm about AtriCure's potential for growth and the untapped opportunities within the Afib treatment sector. CEO Michael Carrel emphasized that Nachman's expertise will be crucial as the company aims to address the needs of an underserved patient population.
Read more →ATRCAtriCure Reports Third Quarter 2023 Financial Results
AtriCure, Inc. reported strong third quarter financial results for 2023, showing an 18.1% year-over-year revenue growth reaching $98.3 million. The company achieved a positive adjusted EBITDA of $4.7 million, an improvement over previous losses. Although the company faced a net loss of $9.1 million, it noted significant advancements in operational efficiency. AtriCure is optimistic about its future growth potential while noting a slight sequential revenue decline due to normal seasonal factors.
Read more →ATRCAtriCure Reports Second Quarter 2023 Financial Results
AtriCure, Inc. reported impressive second quarter 2023 financial results, with worldwide revenue rising to $100.9 million, a 19.4% increase year over year. The company achieved a positive adjusted EBITDA of $8.0 million, an improvement from the previous year, despite a net loss of $5.1 million. Both U.S. and international revenues showed significant growth, highlighting strong demand for their products. Looking ahead, AtriCure projects full-year 2023 revenue in the range of $392 million to $395 million, suggesting continued growth potential.
Read more →ATRCAtriCure Reports First Quarter 2023 Financial Results
AtriCure, Inc. reported strong financial results for the first quarter of 2023, with revenues reaching $93.5 million, a 25.4% increase compared to the previous year. The company experienced robust demand across its product lines, contributing to a significant improvement in its net loss to $6.5 million and a positive adjusted EBITDA of $1.9 million. AtriCure projects revenues for the full year 2023 to be between $385 million and $392 million, reflecting estimated growth of 17% to 19%. However, ongoing challenges, such as supply chain costs and an expected adjusted loss per share, remain a concern for the company.
Read more →ATRCAtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
AtriCure, Inc. reported strong financial results for Q4 and the full year 2022, with worldwide revenue rising 20.4% year-over-year to $330.4 million. Significant growth was observed in both U.S. and international markets, driven by key product lines. However, the company incurred a net loss of $42.7 million for the year despite improved adjusted EBITDA, which was positive in Q4. Looking ahead, AtriCure anticipates revenue growth of 15% to 17% in 2023.
Read more →ATRCAtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022,
AtriCure, Inc. reported preliminary financial results for Q4 and the full year 2022, indicating significant growth in revenue. The company anticipates Q4 2022 revenue to reach around $88 million, marking a 20% increase compared to Q4 2021. For the full year, revenue is expected to be approximately $330.4 million, also showing a growth of approximately 20%. Additionally, AtriCure provided financial guidance for 2023, projecting revenues between $380 million and $387 million and an estimated break-even adjusted EBITDA.
Read more →ATRCAtriCure Reports Third Quarter 2022 Financial Results
AtriCure Reports Third Quarter 2022 Financial Results MASON, Ohio, November 1, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,
Read more →ATRCAtriCure Reports Second Quarter 2022 Financial Results
AtriCure Reports Second Quarter 2022 Financial Results MASON, Ohio, August 2, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,
Read more →ATRCAtriCure Reports First Quarter 2022 Financial Results
AtriCure Reports First Quarter 2022 Financial Results MASON, Ohio, May 3, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, toda
Read more →ATRCAtriCure Launches EnCompass Clamp, a part of Isolator Synergy Ablation System
AtriCure Launches EnCompass Clamp, a part of Isolator Synergy Ablation System New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio - (BUSINESS WIRE) - April 12, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments
Read more →ATRCAtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results MASON, Ohio, February 15, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-opera
Read more →ATRC▲ +7.7%on this news
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021,
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022 MASON, Ohio, January 10, 2022 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial app
Read more →ATRCAtriCure Reports Third Quarter 2021 Financial Results
AtriCure Reports Third Quarter 2021 Financial Results MASON, Ohio, November 3, 2021 - AtriCure, Inc. (Nasdaq ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results.
Read more →ATRCA ugust 4 , 2021  AtriCure Reports Second Quarter 20 2 1 Financial Results MASON, Ohio, August 4 , 2021 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial
AtriCure Reports Second Quarter 2021 Financial Results MASON, Ohio, August 4, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results.
Read more →ATRCJune 15 , 202 1   AtriCure Names Two New Members to the Board of Directors  MASON, Ohio – (BUSINESS WIRE) – June 15 , 2021– AtriCure, Inc. (Nasdaq: ATRC)
AtriCure Names Two New Members to the Board of Directors MASON, Ohio (BUSINESS WIRE) June 15, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman a
Read more →ATRCApril 2 9 , 20 2 1  AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients  FDA approval results in the only label of its kind for more t
AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure's addressable market Superiority trial
Read more →ATRCApril 27 , 2021  AtriCure Reports First Quarter 20 2 1 Financial Results MASON, Ohio, April 27 , 2021 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial f
AtriCure Reports First Quarter 2021 Financial Results MASON, Ohio, April 27, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. Ou
Read more →ATRCApril 8 , 202 1   AtriCure Names B. Kristine Johnson Board Chair  MASON, Ohio – (BUSINESS WIRE) –
AtriCure Names B. Kristine Johnson Board Chair MASON, Ohio (BUSINESS WIRE) April 8, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson ha
Read more →ATRCFebruary 23 , 2021  AtriCure Reports Fourth Quarter 20 20 and Full Year 20 20 Financial Results MASON, Ohio, February 23 , 2021 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator
AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio, February 23, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 202
Read more →ATRCxFEFF; For immediate release January 1 1 , 20 2 1  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, Internatio
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) MASON, Ohio, January 11, 2021 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments fo
Read more →ATRCAnnual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors.
AtriCure Reports Third Quarter 2020 Financial Results MASON, Ohio, November 5, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2020 financial results.
Read more →ATRCthan those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form
AtriCure Announces Angie Wirick as Chief Financial Officer MASON, Ohio, August 6, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down fr
Read more →ATRCJuly 28 , 20 20  AtriCure Reports Second Quarter 20 20 Financial Results · W orldwide revenue of $ 40 . 8 million – a de crease of 30 . 7 % year over year · U.S. revenue of
AtriCure Reports Second Quarter 2020 Financial Results MASON, Ohio, July 28, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results. A
Read more →ATRCAtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio (BUSINESS WIRE)
AtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio (BUSINESS WIRE) May 11, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a pr
Read more →ATRCMay 8 , 20 20  AtriCure Announces Results from CONVERGE IDE Clinical Trial  R esults presented virtually via Heart Rhythm 365 Platform ; show s primary effectiveness superiority in f
AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; shows primary effectiveness superiority in favor of the hybrid Convergent procedure MASON, Ohio (BUSINESS WIRE) May 8, 2020 AtriCure, Inc. (Nasdaq: ATRC), a le
Read more →ATRCApril 13 , 2020  AtriCure Announces CONVERGE IDE Trial Results Accepted for Late - Breaking Clinical Trial Sessions at Annual Heart Rhythm Society ( HRS ) Meeting  MASON , Ohio  
AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting MASON, Ohio April 13, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atria
Read more →ATRCApril 29 , 20 20  AtriCure Reports First Quarter 20 20 Financial Results · W orldwide revenue of $ 5 3 . 2 million – a de crease of 1 . 4 % year over year · U.S. revenue of
AtriCure Reports First Quarter 2020 Financial Results MASON, Ohio, April 29, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results. I
Read more →ATRCApril 9 , 2020  AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update MASON , Ohio — April 9 , 20 20 — AtriCure, Inc. (
AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update MASON, Ohio April 9, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, tod
Read more →ATRCAtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results MASON, Ohio, February 18, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 201
Read more →ATRCxFEFF; For immediate release January 13 , 20 20  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 201 9 Provides Financial Outlook for 2020 MASON, Ohio, January 13 , 20 20 – AtriCure,
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019 Provides Financial Outlook for 2020 MASON, Ohio, January 13, 2020 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) managemen
Read more →ATRCAtriCure Names Two Industry Veterans to Board of Directors
AtriCure Names Two Industry Veterans to Board of Directors MASON, Ohio--(BUSINESS WIRE) December 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prang
Read more →ATRCOctober 30 , 201 9  AtriCure Reports Third Quarter 201 9 Financial Results · W orldwide revenue of $ 5 6 . 6 million – an increase of 13 . 4 % year over year · U.S. revenue
AtriCure Reports Third Quarter 2019 Financial Results MASON, Ohio, October 30, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2019 financial results.
Read more →ATRCMASON, Ohio (BUSINESS WIRE) August 13, 2019 AtriCure, Inc.
Acquisition of SentreHEART MASON, Ohio (BUSINESS WIRE) August 13, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has completed its previously announced acq
Read more →ATRCDefinitive Agreement to Acquire SentreHEART
AtriCure Enters into Definitive Agreement to Acquire SentreHEART Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, O
Read more →ATRCJuly 30 , 201 9  AtriCure Reports Second Quarter 201 9 Financial Results · W orldwide revenue of $ 58.9 million – an increase of 13 . 7 % year over year · U.S. revenue of $
AtriCure Reports Second Quarter 2019 Financial Results MASON, Ohio, July 30, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2019 financial results. O
Read more →ATRCApril 2 5 , 201 9  AtriCure Reports First Quarter 201 9 Financial Results · W orldwide revenue of $ 54.0 million – an increase of 14 . 8 % year over year · U.S. revenue of $
AtriCure Reports First Quarter 2019 Financial Results MASON, Ohio, April 25, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2019 financial results. We
Read more →ATRCFebruary 28 , 201 9   AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results · 2018 Worldwide revenue of $ 201.6 million – an increase of 1 5 . 4 % year ove
AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results MASON, Ohio, February 28, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and related conditions, today announced fourth quarter and full year 2018 financial
Read more →ATRCxFEFF; For immediate release January 7 , 201 9  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018 MASON, Ohio, January 7, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financi
Read more →ATRCAtriCure Reports Third Quarter 2018 Financial Results
AtriCure Reports Third Quarter 2018 Financial Results MASON, Ohio, November 1, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2018 financial results.
Read more →ATRCAtriCure and its business can be found in AtriCure s Annual Report on Form 10-K and Quarterly Reports on Form
Proposed Public Offering of Common Stock MASON, Ohio, October 3, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of
Read more →ATRCAugust 1 , 2018  AtriCure Reports Second Quarter 2018 Financial Results Updates 2018 Financial Outlook · Worldwide revenue of $51.8 million – an increase of 14.5% year over year
AtriCure Reports Second Quarter 2018 Financial Results Updates 2018 Financial Outlook MASON, Ohio, August 1, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second q
Read more →ATRCAtriCure Reports First Quarter 2018 Financial Results
AtriCure Reports First Quarter 2018 Financial Results MASON, Ohio, April 26, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2018 financial results. We
Read more →ATRCxFEFF; For immediate release
AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results MASON, Ohio, February 26, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full
Read more →ATRCxFEFF; For immediate release February 20 , 201 8 AtriC ure Names Scott Drake Board Chairman Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May MASON , Ohio — February 20
AtriCure Names Scott Drake Board Chairman Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May MASON, Ohio February 20, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and le
Read more →ATRCxFEFF; For immediate release January 8 , 201 8  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 201 7 MASON , Ohio , January 8 , 201 8 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading inn
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 MASON, Ohio, January 8, 2018 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financi
Read more →ATRCxFEFF; For immediate release November 1 , 2017  AtriCure Reports Third Quarter 2017 Financial Results · Worldwide revenue of $42.2 million – an increase of 9.9% year over year · U.S. revenue of $
AtriCure Reports Third Quarter 2017 Financial Results MASON, Ohio, November 1, 2017 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2017 financial results.
Read more →ATRCxFEFF; For immediate release July 27 , 2017  AtriCure Reports Second Quarter 2017 Financial Results · Worldwide r evenue of $ 45 .2 million – an increase of 14. 0 % year over year · U.S. revenue
AtriCure Reports Second Quarter 2017 Financial Results MASON, Ohio, July 27, 2017 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results. W
Read more →ATRCxFEFF;   For immediate release
AtriCure Reports First Quarter 2017 Financial Results MASON, Ohio, May 4, 2017 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2017 financial results. Durin
Read more →ATRCxFEFF;  For immediate release
AtriCure Names Two New Members to its Board of Directors MASON, Ohio March 21, 2017 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine J
Read more →ATRCxFEFF; For immediate release February 28 , 2017  AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results · 201 6 revenue of $1 55. 1 million – up 19.5 % · 201 6 U.S. sales of $12 2.
AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results MASON, Ohio, February 28, 2017 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full
Read more →ATRCxFEFF; For immediate release November 11 , 2016  AtriCure Names Sven Wehrwein to its Board of Directors   MASON , Ohio , November 11 , 201 6 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading inn
AtriCure Names Sven Wehrwein to its Board of Directors MASON, Ohio, November 11, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed
Read more →ATRCxFEFF;  Contact: AtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Lewis Gilmartin Group (415) 937-5402 lynn@gilma
Senior Vice President and Chief Financial Officer Investor Relations Contact lynn@gilmartinir.com AtriCure Reports Third Quarter 2016 Financial Results MASON, Ohio October 27, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
Read more →ATRCxFEFF;  Contact: AtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-45 64 awade@atricure.com Investor Relations Contact Lynn Pieper Gilmartin Group ( 415 ) 937-5402 l ynn@ gilmar
Senior Vice President and Chief Financial Officer Investor Relations Contact lynn@gilmartinir.com AtriCure Announces $25 Million Term Loan with Silicon Valley Bank MASON, Ohio April 28, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillat
Read more →ATRCAtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Gilmartin Group (415) 309-5999 lynn@gilmartinir.com AtriCure Re
Senior Vice President and Chief Financial Officer Investor Relations Contact lynn@gilmartinir.com AtriCure Reports Fourth Quarter and Full Year 2015 Financial Results MASON, Ohio February 23, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fib
Read more →ATRCAtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-45 64 awade@atricure.com Investor Relations Contact Lynn Pieper Westwicke Partners ( 415 ) 202-5678 l ynn.pieper@westwicke.com
Senior Vice President and Chief Financial Officer Investor Relations Contact lynn.pieper@westwicke.com AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance MASON, Ohio January 11, 2016 AtriCure, Inc. (Nasdaq: ATRC), a leading inn
Read more →ATRCAtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Westwicke Partners (415) 202-5678 lynn.pieper@westwicke.com Atr
Senior Vice President and Chief Financial Officer Investor Relations Contact lynn.pieper@westwicke.com AtriCure Reports Third Quarter 2015 Financial Results WEST CHESTER, Ohio October 27, 2015 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrill
Read more →ATRCOctober 13 , 2015 AtriCure Completes Acquisition of nContact WEST CHESTER, Ohio – October 13 , 2015 – AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibr
AtriCure Completes Acquisition of nContact WEST CHESTER, Ohio October 13, 2015 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has completed its previously announced acq
Read more →ATRCOctober 4 , 2015 AtriCure Enters Into Definitive Agreement to Acquire nContact An nounces Preliminary Results for Third Quarter 2015 , Updates Outlook for 2015 and Provides 2016 Outlook Company to H
AtriCure Enters Into Definitive Agreement to Acquire nContact Announces Preliminary Results for Third Quarter 2015, Updates Outlook for 2015 and Provides 2016 Outlook Company to Host Conference Call Monday, October 5 at 8:30am ET Acquisition expands available market opportunit
Read more →ATRCAtriCure, Inc. (Nasdaq: ATRC) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Mar. 23, 2015 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Michael H. Carrel, Pres
Read more →ATRCAtriCure, Inc. Andy Wade Senior Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact: Lynn Pieper Westwicke Partners (415) 202-5678 Lynn.pieper@westwicke.com Do
Senior Vice President and Chief Financial Investor Relations Contact: Lynn.pieper@westwicke.com Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President WEST CHESTER, Ohio January 14, 2015 AtriCure, Inc. (Nasdaq: ATRC), a leading inno
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Westwicke Partners (415) 202-5678 lynn.pieper@westwicke.com AtriCure A
Vice President and Chief Financial Officer Investor Relations Contact lynn.pieper@westwicke.com Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance WEST CHESTER, Ohio January 12, 2015 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical t
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Westwicke Partners (415) 202-5678 lynn.pieper@westwicke.com AtriCure R
Vice President and Chief Financial Officer Investor Relations Contact lynn.pieper@westwicke.com Third Quarter 2014 Financial Results and Updates 2014 Outlook October 30, 2014 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (
Read more →ATRCAtriCure to Announce Third Quarter 2014 Financial Results
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 20
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact: Lynn Pieper Westwicke Partners (415) 202-5678 lynn.pieper@westwicke.com AtriCure
Vice President and Chief Financial Officer Investor Relations Contact: lynn.pieper@westwicke.com Commencement of Public Offering of Common Stock WEST CHESTER, Ohio February 12, 2014 AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today a
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact Lynn Pieper Westwicke Partners (415) 202-5678 lynn.pieper@westwicke.com AtriCure C
Vice President and Chief Financial Officer Investor Relations Contact lynn.pieper@westwicke.com Acquisition of Estech WEST CHESTER, Ohio January 2, 2014 AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of th
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact: Lynn Pieper Westwicke Partners (415) 202-5678 Lynn.pieper@westwicke.com AtriCure
Vice President and Chief Financial Officer Investor Relations Contact: Lynn.pieper@westwicke.com AtriCure Reports First Quarter 2013 Financial Results WEST CHESTER, Ohio May 2, 2013 AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of tec
Read more →ATRCAtriCure, Inc. Andy Wade Vice President and Chief Financial Officer (513) 755-4564 awade@atricure.com Investor Relations Contact: Lynn Pieper Westwicke Partners 415-202-5678 Lynn.pieper@westwicke.com For Immedia
Vice President and Chief Financial Officer Lynn.pieper@westwicke.com AtriCure Announces Commencement of Public Offering of Common Stock WEST CHESTER, Ohio January 15, 2013 AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation system
Read more →ATRCAtriCure, Inc. Andy Wade Vice President, Finance (513) 755-4564 awade@atricure.com Investor Relations Contact: Lynn Pieper Westwicke Partners 415-202-5678 Lynn.pieper@westwicke.com AtriCure Announces Preliminary
Vice President, Finance Investor Relations Contact: Lynn.pieper@westwicke.com AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2012 WEST CHESTER, Ohio January 7, 2013 AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgic
Read more →ATRCAtriCure, Inc. Investor Relations Andy Wade Lynn Pieper Vice President, Finance Westwicke Partners (513) 755-4564 (415) 202-5678 awade@atricure.com lynn.pieper@westwicke.com AtriCure Reports Third Quarter 2012 F
AtriCure, Inc. Investor Relations Andy Wade Lynn Pieper Vice President, Finance Westwicke Partners (513) 755-4564 (415) 202-5678 awade@atricure.com lynn.pieper@westwicke.com AtriCure Reports Third Quarter 2012 Financial Results WEST CHESTER, Ohio November 1, 2012 AtriCure,
Read more →Competitive Position
How ATRC ranks across every disease it competes inCompetitive Position is a premium feature
See how ATRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial